Hirano, H., Takahashi, N., Amanuma, Y., Suzuki, N., Takahari, D., Kawakami, T., . . . Shoji, H. Phase II trial of nab-paclitaxel plus ramucirumab in combination with nivolumab for unresectable advanced or recurrent gastric cancer after progression on first-line treatment including fluoropyrimidine, platinum, and anti-PD-1/PD-L1 antibody (PADDLE). BMC.
Chicago Style (17th ed.) CitationHirano, Hidekazu, et al. Phase II Trial of Nab-paclitaxel Plus Ramucirumab in Combination with Nivolumab for Unresectable Advanced or Recurrent Gastric Cancer After Progression on First-line Treatment Including Fluoropyrimidine, Platinum, and Anti-PD-1/PD-L1 Antibody (PADDLE). BMC.
MLA (9th ed.) CitationHirano, Hidekazu, et al. Phase II Trial of Nab-paclitaxel Plus Ramucirumab in Combination with Nivolumab for Unresectable Advanced or Recurrent Gastric Cancer After Progression on First-line Treatment Including Fluoropyrimidine, Platinum, and Anti-PD-1/PD-L1 Antibody (PADDLE). BMC.